Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Created from data from the Behavioral Risk Factor Surveillance System Survey
It has no approval from regulatory agencies such as the FDA for human use and remains in the preclinical research phase
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Subcutaneous injection near injury sites or systemic administration both show effectiveness
Test each eye separately, daily or weekly, documenting any changes (missing lines, wavy lines, dark spots)
To minimize contamination during reconstitution and to maintain the integrity of the compound at all times, aseptic procedures should be carefully observed during this process
